BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Oxford GlycoSciences (UK) Ltd submitted on 29 June 2001 an application for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
through the centralised procedure for Zavesca, which was designated as an orphan medicinal product 
EU/3/00/006 on 18 October 2000.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr Per Nilsson 
Co-Rapporteur: 
Prof Rolf Bass 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 17 July 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  26 
September  2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 27 September 2001. 
During the  meeting on 13 – 15 November  2001 the CPMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 15 November 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  23 
January 2002. 
The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  site  on  11  December 
2001 was issued on 12 February 2002. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 25 February 2002. 
During the meeting on 19 – 21 March 2002 the CPMP adopted a list of outstanding issues to be 
addressed by the applicant in writing. The list of outstanding issues was sent to the applicant on 
21 March 2002. 
The applicant provided written information on these outstanding issues to all CPMP members 
on  26  April  2002  and  15  May  2002.  The  Rapporteur/Co-Rapporteurs’  joint  review  on  the 
responses to the list of outstanding issues was circulated to all CPMP members on 14 May 2002 
and an amended version on 22 May 2002. 
Concurrent  with  the  CPMP  meeting  on  25  -  27  June  2002,  an  ad-hoc  clinical  expert  meeting 
took place on 24 June 2002 and a report was adopted by the CPMP on 27 June 2002.   
During  the  CPMP  meeting  on  25  –  27  June  2002,  outstanding  issues  were  addressed  by  the 
applicant on 25 June 2002 during an oral hearing before the CPMP. 
The  applicant  provided  written  information  to  all  CPMP  Members  on  15  July  2002.  The 
Rapporteur/Co-Rapporteurs’ joint review of the written information was circulated to all CPMP 
members on 16 July 2002. 
During the meeting on 23 – 25 July 2002 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Zavesca on 25 July 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 20 November 2002. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
